



R O S I A

REMOTE REHABILITATION SERVICE FOR ISOLATED AREAS

**PCP End of Phase III**  
**Rehablify - Results &**  
**conclusions**

<b>Document type</b>	Grant deliverable
<b>Document version</b>	Final
<b>Document Preparation Date</b>	[29/10/2025]
<b>Classification</b>	Public (except for the parts marked as 'not suitable for publication')
<b>Author(s)</b>	All project partners
<b>File Name</b>	ROSIA PCP End of phase — Rehablify results and conclusions



## Contactors

### 1. The innovative solution

*Provide a short description:*

**The innovative solution** (in its current form)

Rehablify is a comprehensive telerehabilitation platform that enables remote, personalised, and multidisciplinary rehabilitation through a unified digital ecosystem designed to connect patients, healthcare professionals, and third-party developers.

At its core, Rehablify follows a **three-axis system-based approach** that brings together all actors of the rehabilitation process.

- The **Rehablify Backoffice** is a professional web portal that allows healthcare staff to manage patients, configure shared care plans, prescribe exercises and questionnaires, and monitor progress in real time. It supports integrated-care pathways by combining clinical information, communication tools, and data-driven decision support to facilitate coordinated teamwork among physiotherapists, doctors, nurses, and psychologists.
- The **Rehablify App** acts as the patient's personal gateway to the rehabilitation process. Through it, individuals can follow prescribed exercises, complete assessments, exchange messages or videocalls with their care team, and receive personalised guidance to support self-management, behavioural change, and long-term adherence. By maintaining continuous interaction between professionals and patients, the app promotes empowerment and continuity of care at home or in remote areas.
- Finally, **Rehablify Developers** provides an open ecosystem that allows **Third-Party Solutions (TPS)** to integrate easily via secure APIs, SDKs, and a structured certification framework. This developer portal fosters an innovation community around the **ROSIA Open Platform**, offering documentation, communication channels, code samples, and validation tools. TPS can be seamlessly added to the Rehablify catalogue, expanding clinical capabilities through interoperable digital rehabilitation to ols and connected devices.

During **Phase 3 of ROSIA**, Rehablify was **clinically validated across three healthcare systems**: SALUD Aragón (Spain), the National Rehabilitation Hospital (Ireland), and Centro Hospitalar e Universitário de Coimbra (Portugal). Over six months of deployment, it integrated **eight certified Third-Party Solutions** covering seven key pathologies (COPD, stroke, spinal-cord injury, acquired brain injury, cardiovascular disease, hip fracture, knee arthroplasty, and post-COVID-19 recovery). These pilots confirmed the platform's flexibility, interoperability, and capacity to adapt to diverse clinical workflows and regulatory contexts.

**Where exactly lies the innovativeness in the solution:** In which ways and to which extent does the solution go beyond what existing solutions can achieve

Rehablify goes beyond existing telerehabilitation solutions by delivering the **first operational implementation of the ROSIA Open Platform**, a model that unites clinical, technological, and innovation dimensions within a single interoperable ecosystem.

The solution combines:

- **A modular, open architecture** interoperable with heterogeneous healthcare systems (FHIR, HL7, LOINC), ensuring secure data exchange and integration with institutional IT infrastructures.
- **A shared care plan** that connects multidisciplinary teams and synchronises patient data across care settings, supporting truly integrated rehabilitation pathways.
- **A developer ecosystem and open portal** offering SDKs, APIs, and documentation to facilitate the integration of external telerehabilitation apps, devices, and digital services, thereby accelerating innovation.
- **An AI-based recommendation and decision support system**, developed under the ROSIA framework, to assist professionals in tailoring personalised care plans and exercise prescriptions based on patient profiles and progress.
- **A governance and certification system** that guarantees quality, ethical compliance, and technical validation for Third-Party Solutions (TPS) integrated into the platform (Label2Enable)
- **A scalable marketplace model** that promotes sustainability and continuous growth of the ecosystem beyond the PCP, enabling new providers to offer validated services through the platform.

Its human-centered design, developed through weekly co-creation with clinicians and patients, ensures that rehabilitation can continue seamlessly across hospitals, community, and home environments; a key enabler for continuity of care in rural or remote regions.

**The degree of innovation:** indicate if your innovative solution is (a) a totally new product / service / process / method; (b) an improvement to an existing product / service / process / method; (c) a new combination of existing products / services / processes / methods (d) a new use for existing products / services / processes / methods)

(c) **A new combination of existing technologies and processes**, integrating professional, patient, and developer tools into a single interoperable telerehabilitation ecosystem.



## 2. Other benefits obtained

ROSIA has generated a wide range of tangible and intangible benefits for the Rehabilify consortium: Eurecat, Doole Health, and IGTP, extending well beyond the direct technological outcomes.

**Getting easier access to (a new segment of) the public procurement market** (did the procurement enable you to work with procurers/end-users that you were not working with beforehand)

The PCP enabled Eurecat and Doole Health to work directly with three new public healthcare systems (*SALUD Aragón, CHUC and NRH*) that were not previous customers or collaborators.

Through this engagement, the consortium gained:

- **First-hand experience in public procurement** procedures at international level, including ethical, technical, and interoperability frameworks.
- **Recognition as a qualified provider** of digital health innovation within public procurement contexts.
- **Institutional references** that now serve as strong credentials for future tenders in Spain and across the EU.

**Growing your business across borders and/or to other markets** (e.g. *private markets*) thanks to the first customer references provided by the procurement

Participation in ROSIA positioned Rehabilify as a **pan-European telerehabilitation platform**, validated across **three countries and seven pathologies**.

This cross-border deployment created:

- **Visibility and partnerships** with over **15 Third-Party Solution (TPS) providers** from several EU countries.
- **Interest from nine new hospitals** and rehabilitation centres identified during dissemination events (e.g. MWC, Health Revolution Congress, XPatient)
- A foundation for **expansion to private markets** through the upcoming *Rehabilify Lite* SaaS version, which lowers adoption barriers for clinics and small institutions.

These results have effectively opened doors for **growth beyond national borders** and established the consortium's footprint in the European digital-health market.

**Shortening the time-to-market for your innovation** thanks to early customer/end-user feedback

The PCP process, particularly the **weekly co-creation meetings with clinicians and procurers**, provided continuous user feedback, leading to **14 app releases and 12 back-office updates** during the pilot.

This accelerated:

- The validation of functionalities under real clinical workflows.
- The identification and correction of usability gaps.
- The design of a **commercial-ready "Lite" version**, directly informed by end-user needs.

Consequently, the expected time-to-market was reduced by at least **two years** compared with a traditional development cycle.

**Other benefits / lessons learnt:** complete if applicable

Beyond market and product outcomes, the PCP also generated several strategic and organisational benefits for the consortium. The collaboration between Eurecat, Doole Health, and IGTP was significantly strengthened, consolidating their complementary R&D, clinical, and commercial expertise into a cohesive partnership. Participation in ROSIA enhanced the consortium's experience in public innovation procurement (PCP) and advanced their mastery of interoperability standards such as FHIR and HL7, as well as GDPR and ethical compliance across different European healthcare systems.

The project also reinforced the institutional reputation of the partners, positioning Rehabilify as part of Eurecat's HealthTech Portfolio and as a key digital-care solution within Doole Health's offering. At the clinical level, it fostered knowledge transfer and capacity building among healthcare teams, expanding their skills in remote rehabilitation and telehealth practices. Finally, the project validated an open innovation model, successfully demonstrated through the integration and certification of eight TPS within the ROSIA Catalogue, an achievement that underscores Rehabilify's scalability and ecosystem-driven approach.

**Lessons learned for future procurements** highlight several key factors that contributed to the success of the project and should be considered in future innovation partnerships. First, it is essential to engage ethical committees and procurers early in the process to anticipate regulatory requirements and avoid approval bottlenecks. Equally important is the need to combine flexibility with standardisation, ensuring that the solution can adapt to local healthcare contexts while maintaining interoperability and scalability across regions. The project also demonstrated that robust user-support systems, including comprehensive training, helpdesk services, and structured ticketing, are critical to enabling adoption by clinicians and patients alike. Finally, future PCPs should plan



sufficient resources and time for iterative updates, as real-world testing inevitably reveals new functional needs and improvement opportunities that are key to achieving a mature, clinically validated product.

### 3. Business growth

*Provide a short description:*

#### How much has your business already grown during the procurement

In terms of (a) personnel growth; (b) turnover growth; (c) growth in market share etc.

During the PCP, the Rehablify consortium (Eurecat, Doole Health and IGTP) experienced relevant growth in organizational capacity, visibility, and market positioning.

**Personnel growth:** The project required additional technical and clinical expertise in AI, interoperability, and UX design. Eurecat strengthened its digital-health team with new engineers and data-science staff; Doole Health expanded its development team to cover integration, testing, and support for the three pilot sites; and IGTP reinforced its clinical research group with coordination and data-management profiles.

**Turnover and portfolio growth:** The ROSIA contract contributed to stable revenues and improved sustainability for all partners. Eurecat used the results to expand its HealthTech portfolio and secure new national and European innovation projects building on Rehablify's achievements. Doole Health consolidated its presence in the digital-care market, using Rehablify as a reference solution in ongoing collaborations with hospitals.

**Market share and positioning:** Through ROSIA, the consortium gained visibility in Spain, Portugal, and Ireland as a reference actor in telerehabilitation and open-platform ecosystems, achieving TRL 7 and validation in real healthcare environments. Rehablify is now recognized as a credible, CE-ready solution for continuity-of-care and remote rehabilitation.

#### What are the prospects to grow your business via wider commercialisation of the solution:

- how large is the potential market for your solution? is it a growing / steady / declining market?
- by when can commercialisation start (now / in 1 / in 3 / in 5 / in more than 5 years)
- is competition patchy (no major players) / established (but no comparable offering) / fierce
- 

The growth outlook is positive, supported by clear market demand and strong differentiation.

**Market potential and growth rate:** The European telerehabilitation market is rapidly expanding, driven by ageing populations, chronic-disease management, and post-COVID adoption of tele-care. Demand for interoperable, patient-centred rehabilitation tools is high, while existing offerings remain fragmented and often pathology-specific. The market is growing and moderately competitive, with significant space for scalable, open-ecosystem platforms like Rehablify.

**Commercialisation timeline:** Rehablify has completed full clinical validation and achieved TRL 7. The Pro (hospital-integrated) version, which corresponds to the complete solution piloted during Phase 3, is already ready for commercialization. It can be deployed immediately and tailored to each healthcare provider, with specific integrations and modules agreed upon according to institutional needs. In parallel, the Lite (SaaS) version (offering a simplified, plug-and-play model with reduced functionalities and no hospital integration), is scheduled for commercial launch in 2026, enabling faster onboarding and scalability for smaller organizations or early adopters.

**Competition landscape:** The field is established but fragmented: several proprietary telerehabilitation tools exist, but none combine professional, patient, and developer environments in an open, certified ecosystem. This provides a clear competitive advantage for Rehablify.

